- Home
- BMEZ vs BEAM Comparison
BMEZ vs BEAM Comparison
Compare BMEZ & BEAM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BMEZ
- BEAM
- Stock Information
- Founded
- BMEZ N/A
- BEAM 2017
- Country
- BMEZ United States
- BEAM United States
- Employees
- BMEZ N/A
- BEAM N/A
- Industry
- BMEZ Trusts Except Educational Religious and Charitable
- BEAM Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- BMEZ Finance
- BEAM Health Care
- Exchange
- BMEZ Nasdaq
- BEAM Nasdaq
- Market Cap
- BMEZ 1.5B
- BEAM 1.6B
- IPO Year
- BMEZ N/A
- BEAM 2020
- Fundamental
- Price
- BMEZ $14.47
- BEAM $21.16
- Analyst Decision
- BMEZ
- BEAM Strong Buy
- Analyst Count
- BMEZ 0
- BEAM 11
- Target Price
- BMEZ N/A
- BEAM $48.90
- AVG Volume (30 Days)
- BMEZ 391.3K
- BEAM 2.2M
- Earning Date
- BMEZ 01-01-0001
- BEAM 08-05-2025
- Dividend Yield
- BMEZ 8.71%
- BEAM N/A
- EPS Growth
- BMEZ N/A
- BEAM N/A
- EPS
- BMEZ 0.54
- BEAM N/A
- Revenue
- BMEZ N/A
- BEAM $63,578,000.00
- Revenue This Year
- BMEZ N/A
- BEAM N/A
- Revenue Next Year
- BMEZ N/A
- BEAM $17.18
- P/E Ratio
- BMEZ $30.17
- BEAM N/A
- Revenue Growth
- BMEZ N/A
- BEAM N/A
- 52 Week Low
- BMEZ $12.93
- BEAM $13.53
- 52 Week High
- BMEZ $16.95
- BEAM $35.25
- Technical
- Relative Strength Index (RSI)
- BMEZ 51.74
- BEAM 65.49
- Support Level
- BMEZ $14.22
- BEAM $19.02
- Resistance Level
- BMEZ $14.62
- BEAM $22.51
- Average True Range (ATR)
- BMEZ 0.19
- BEAM 1.15
- MACD
- BMEZ 0.02
- BEAM 0.49
- Stochastic Oscillator
- BMEZ 71.87
- BEAM 78.91
About BMEZ BlackRock Health Sciences Term Trust of Beneficial Interest
BlackRock Health Sciences Trust II is a closed-ended management investment company. The investment objective is to provide total return through a combination of current income and long-term capital appreciation. The Trust seeks to achieve its investment objective by investing, under normal market conditions, at least 80% of its total assets in equity securities of energy and natural resources companies and equity derivatives with exposure to the energy and natural resources industry.
About BEAM Beam Therapeutics Inc.
Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company views its operations and manages its business in one operating segment, operating exclusively in the United States.